Quick Answer
Dogwood Therapeutics, Inc. reported Net Income of -$34.26 million for fiscal year 2025.
Dogwood Therapeutics, Inc. Net Income — Annual History
| Fiscal Year | Net Income | YoY Change |
|---|---|---|
| 2025 | -$34.26M | -177.4% |
| 2024 | -$12.35M | -133.2% |
| 2023 | -$5.30M | +56.8% |
| 2022 | -$12.25M | +23.3% |
| 2021 | -$15.96M | -54.3% |
| 2020 | -$10.35M | — |
Quarterly Net Income
| Quarter Ending | Net Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$15.74M | -590.3% | -313.5% |
| June 30, 2025 | -$3.81M | -262.7% | +65.1% |
| March 31, 2025 | -$10.92M | -746.0% | -379.0% |
| September 30, 2024 | -$2.28M | -84.7% | -117.2% |
| June 30, 2024 | -$1.05M | +27.1% | +18.7% |
| March 31, 2024 | -$1.29M | +14.9% | -4.6% |
| September 30, 2023 | -$1.24M | +52.0% | +14.3% |
| June 30, 2023 | -$1.44M | +60.7% | +5.0% |
- Dogwood Therapeutics, Inc. showed a decrease of -177.4% in Net Income compared to the prior fiscal year.
- Over the 2020–2025 period, Dogwood Therapeutics, Inc.’s net income has declined by 231.1% (from -$10.35 million to -$34.26 million).
- The most recent figure is from Dogwood Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 18, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: